Enterococci are Gram-positive, facultative anaerobic oval cocci found in the gastrointestinal tract of virtually all animals, including humans. They are usually harmless but pose a serious threat in immunocompromised patients or patients with dysbiosis caused by antibiotic therapy, such as endocarditis, bacteremia, and intra-abdominal, wound, and urinary tract infections. Enterococci are thus a major cause of infection in hospital intensive care units.
Fig.1 Proposed physiological roles of Enterococcus faecalis polysaccharides in the gut. (Ramos, et al., 2021)
E. faecalis and Enterococcus faecium are the most common clinical opportunistic pathogens. Their pathogenicity is mainly attributed to intrinsic antibiotic resistance, the ability to acquire virulence factors, and the ability to tolerate and grow in harsh environments. Enterococci possess a highly diverse array of glycobiology, and they not only can build essential structural polysaccharides, but also synthesize capsular polysaccharide (CPS), lipoteichoic acid (LTA), and other exopolysaccharides. Antibodies against CPS promote polymorphonuclear neutrophils (PMN)-mediated killing of E. faecalis and E. faecium and protect mice from enterococcus infection, the study showed.
The growing prevalence of antimicrobial-resistant pathogens has facilitated the identification of new vaccine targets. At CD BioGlyco, we have established a Glyco™ Vaccine Development Platform against multiple pathogens, such as meningococcal, Haemophilus influenzae, and enterococcal. All enterococci produce a complex polysaccharide called the enterococcal polysaccharide antigen (EPA). This polymer is required for normal cell growth and division, as well as for resistance to antibiotics. It plays a key role in host-pathogen interactions. Therefore, we provide EPA production development services for our global clients.
Case: E. faecium surface polysaccharide production service
Fig.2 Flowchart of E. faecium polysaccharide production. (CD BioGlyco)
As a best-in-class Polysaccharide Vaccine Development company, CD BioGlyco is committed to helping clients solve the difficulties and problems in the development of polysaccharide vaccines against multiple pathogens. If you are interested in our service, please feel free to contact us for more information.
References: